Twofold distinction for the Europe-wide registry on alpha1-antitrypsin deficiency-related liver disease

Alpha1-antitrypsin deficiency (AAT deficiency) is a frequently overlooked metabolic disorder. Apart from lung disease, AAT deficiency leads to liver disease in up to 50% of patients. Although involvement of the liver is the second most common cause of decreased quality of life and life expectancy in Alpha1 patients, no preventative care plan, like that one implemented to avoid lung involvement, has yet been drawn up. To close this gap, the Clinic for Gastroenterology and the Center for rare liver diseases of the University Hospital Aachen (Germany) under the leadership of Dr. Pavel Strnad initiated a multicenter registry study. This study has now been distinguished by two European organizations: the development of this registry is supported financially and politically by the European Reference Networks „RARE-LIVER" and the „European Association for the Study of the Liver (EASL)".

Here you can find the <link file:14966 download file>press release.